Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

Alyftrek is approved to treat people ages 6 and older who have the genetic condition called cystic fibrosis. Cystic fibrosis happens because of a change in a gene on chromosome 7.

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has approved ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis transmembrane ...

ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced ...

Alyftrek once daily (vanzacaftor 20 mg/tezacaftor 100 mg/deutivacaftor 250 mg) or; ELX/TEZ/IVA (same dosage as run-in period). The primary endpoint was absolute change in percent predicted forced ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

ALYFTREK is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B) and should only be considered when there is a clear medical need, and benefit outweighs risk.

ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced ...